Evidence map›Paper›PMID 41691491›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Selective Targeting of Tip Endothelial Cells as a Therapeutic Strategy for Tumor Angiogenesis.

Byoungmo Kim, Ha Kyeong Lee, Zulfikar Azam, Jeong Uk Choi, Riajul Wahab, Na Kyeong Lee, Yoon Gun Ko, So-Young Choi, Se-Ra Lee, Wan Seob Shim and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Byoungmo KimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-8594-6775
Ha Kyeong LeeCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-2727-897X
Zulfikar AzamDepartment of Molecular Pharmaceutics and Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-8122-9506
Jeong Uk ChoiCollege of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-3168-7189
Riajul WahabDepartment of Molecular Pharmaceutics and Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-5967-4419
Na Kyeong LeeCollege of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.ORCID https://orcid.org/0000-0002-6461-4445
Yoon Gun KoPharosgen Co. Ltd, Seoul, Republic of Korea.
So-Young ChoiNew Drug Development Center Osong Medical Innovation Foundation 123 Osongsaengmyeong-ro, Heungdeok-gu, Cheongju, Chungbuk, Republic of Korea.
Se-Ra LeeNew Drug Development Center Osong Medical Innovation Foundation 123 Osongsaengmyeong-ro, Heungdeok-gu, Cheongju, Chungbuk, Republic of Korea.
Wan Seob ShimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
Taeeung KimCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
In-San KimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-1714-4521
Farzana AlamDepartment of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA.
Sang Yoon KimPharosgen Co. Ltd, Seoul, Republic of Korea.
Seong Who KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID https://orcid.org/0000-0002-3731-9109
Youngro ByunCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-3863-2236
Taslim A Al-HilalDepartment of Molecular Pharmaceutics and Biomedical Engineering, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-9189-776X

Funding

Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and ImmunityR01CA262788 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Taslim A Al-Hilal · 2022 to 2026
$1.4M
The role of tumor endothelium-specific prion-gene PRND in epithelial ovarian cancerR21CA264627 · NCI · UNIVERSITY OF UTAH · PI AL-HILAL, TASLIM A · 2022 to 2023
$387k
DOD Peer Reviewed Cancer Research Program DoD HT94252410217Korea Drug Development Fund HN21C0264Korea government 2020R1A2C2015026Lizanell and Colbert Coldwell Foundation NAID20220187NCI NIH HHS NIH R01CA262788NCI NIH HHS NIH R21CA264627NCI NIH HHS R01 CA262788NCI NIH HHS R21 CA264627NIGMS NIH HHS NIH SC1GM144171Small Business Technology Transfer HT942523C0044
6 · The paper itself

Abstract

Tip endothelial cells (

Indexed as

Endothelial CellsNeoplasmsNeovascularization, PathologicAnimalsHumansMiceVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor Receptor-2angiogenesismonoclonal antibodiestip cellstumor therapy

Identifiers

PMID41691491
PMCPMC13042361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.